Hims & Hers Defies FDA Crackdown with 3.98% Surge, Ranks 381st in Market Activity

Market Snapshot

Hims & Hers Health (HIMS) closed with a 3.98% price increase on March 4, 2026, despite a 23.64% decline in trading volume to $0.33 billion, ranking the stock 381st in market activity for the day. The mixed performance followed heightened regulatory scrutiny and operational adjustments tied to its compounded GLP-1 drug offerings.

Key Drivers

The U.S. Food and Drug Administration (FDA) intensified its crackdown on telehealth companies marketing compounded GLP-1 drugs, sending 30 warning letters to firms—including Hims & Hers—accusing them of “false and misleading claims.” These products, marketed as lower-cost alternatives to branded therapies like Novo Nordisk’s Ozempic and Wegovy, have become a regulatory flashpoint. Hims & Hers had surged over 13% in the prior session but reversed course following the FDA’s enforcement action, underscoring investor sensitivity to regulatory risks.

A critical blow came last month when Hims & Hers suspended sales of a compounded version of Novo’s Wegovy tablet after regulatory scrutiny escalated. The company had previously faced criticism for its marketing practices around compounded semaglutide-based products, and the FDA’s recent warnings reinforce concerns about the legality and safety of such offerings. FDA Commissioner Marty Makary emphasized the agency’s commitment to monitoring advertising claims across all media platforms, signaling a broader enforcement strategy that began in September with 100 letters targeting pharmaceutical false advertising.

The regulatory environment casts uncertainty over Hims & Hers’ business model, which relies heavily on compounded GLP-1 sales. The company’s CEO, Andrew Dudum, has stated it can adapt to a scenario where compounding GLP-1s are restricted, but analysts remain skeptical. Recent downward revisions to price targets—averaging $20.70 from $29.42—reflect doubts about the company’s ability to sustain growth amid regulatory headwinds and litigation from Novo Nordisk. Additionally, Hims & Hers disclosed an SEC investigation in February, compounding investor concerns.

While the company is pursuing international expansion—planning to acquire Australia’s Eucalyptus for $1.15 billion and already expanding into the UK—these efforts face financial pressures. The weight-loss segment is expected to incur a $65 million revenue headwind in Q1 2026, and analysts question whether the company can achieve its 2030 $6.5 billion revenue goal without a diversified revenue base. Regulatory changes, such as potential additions to the FDA’s “do-not-compound” list for semaglutide, could further disrupt operations.

The stock’s 3.98% gain on March 4 suggests some optimism about Hims & Hers’ long-term strategy, but the broader regulatory and legal challenges remain unresolved. With the FDA’s enforcement actions and Novo’s litigation ongoing, the company’s ability to navigate these risks will be pivotal in determining its future performance.